SequelSEC

PRECISION BIOSCIENCES INC DTIL

Biological Products, (No Diagnostic Substances) · CIK 0001357874 · Fiscal year ends 0521

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2026-06-30
Operating income
-$19.16M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

PRECISION BIOSCIENCES INC (DTIL) reported revenue of $0 and net income of -$32.65M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PRECISION BIOSCIENCES INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

PRECISION BIOSCIENCES INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$0$10.84M$34.20M$13.00K$18.00K$29.00K$638.00K$576.00K$49.90M$17.58M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$19.16M-$9.08M$12.51M-$20.67M-$21.88M-$22.11M-$24.85M-$21.28M$24.15M-$4.19M
Net income-$32.65M-$18.44M$20.13M-$21.77M-$23.52M-$20.56M-$17.74M-$16.42M$32.75M$8.59M
Research & development$12.39M$13.11M$14.46M$13.35M$12.77M$13.59M$15.91M$13.08M$17.22M$13.34M
Weighted-average diluted sharesshares 25.86Mshares 24.63MUnavailableshares 11.82Mshares 11.05Mshares 9.29MUnavailableshares 7.29Mshares 7.01Mshares 5.06M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.26$-0.75Unavailable$-1.84$-2.13$-2.21Unavailable$-2.25$4.67$1.70
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.77M$6.80M$7.23M$7.33M$9.13M$8.55M$9.58M$8.77M$8.53M$8.43M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PRECISION BIOSCIENCES INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$86.08M$99.37M$110.82M$44.87M$62.24M$77.22M$85.90M$98.75M$123.57M$137.77M
Total assets$125.92M$143.89M$154.42M$93.51M$108.93M$124.41M$136.39M$153.26M$165.80M$184.74M
Current assets$91.55M$108.69M$118.74M$51.70M$70.26M$82.10M$94.99M$110.52M$144.04M$160.83M
Total liabilities$80.63M$67.79M$62.17M$76.88M$74.87M$75.07M$80.00M$88.39M$91.09M$147.54M
Current liabilities$7.14M$7.76M$8.91M$15.00M$13.57M$12.39M$14.98M$11.98M$32.96M$33.34M
Total equity incl. NCI$45.29M$76.10M$92.25M$16.63M$34.05M$49.34M$56.39M$64.87M$74.71M$37.21M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$0$4.00M$0$4.00K$0$4.00K$229.00K$188.00K$207.00K$390.00K
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$828.00K$944.00K$296.00K$1.34M$1.12M$924.00K$1.31M$958.00K$1.14M$1.14M

Cash flow

PRECISION BIOSCIENCES INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$13.44M-$11.94M-$11.25M-$15.27M-$20.27M-$19.05M-$18.68M-$5.91M-$14.87M-$18.98M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$1.00K-$114.00K-$325.00K$17.00K-$12.00K-$314.00K-$97.00K-$64.00K-$28.00K-$26.00K
Financing cash flow$0$745.00K$77.52M$1.66M$5.30M$10.69M$5.92M$3.73M$702.00K$40.10M
Net change in cash-$13.44M-$11.31M$65.94M-$13.59M-$14.98M-$8.68M-$12.86M-$2.24M-$14.20M$21.09M
Stock-based compensation$1.84M$1.55M$2.04M$2.39M$2.94M$2.82M$3.57M$3.20M$2.93M$2.91M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$253.00K$299.00K$345.00K$350.00K$378.00K$395.00K$454.00K$715.00K$1.09M$1.14M

Derived

PRECISION BIOSCIENCES INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailable-83.7%36.6%-158976.9%-121538.9%-76248.3%-3894.4%-3693.6%48.4%-23.8%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailable14.3%6.0%18353.8%16316.7%9731.0%559.7%555.4%5.9%16.5%
Current ratio12.82x14.02x13.32x3.45x5.18x6.62x6.34x9.22x4.37x4.82x
Revenue YoY growth-100.0%37272.4%5261.1%-97.7%-100.0%-99.8%-90.9%-95.6%152.2%100.3%
Net marginUnavailableUnavailable58.9%-167476.9%-130666.7%Unavailable-2781.3%-2851.6%UnavailableUnavailable
R&D / revenueUnavailable121.0%42.3%102707.7%70933.3%46855.2%2493.3%2271.5%34.5%75.9%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DTIL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-05View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-03View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.